The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
 
D. Ross Camidge
No Relationships to Disclose
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie; Celgene; Debiopharm Group; Exelixis; GlaxoSmithKline; Incyte; Millennium; Mirati Therapeutics; Novartis; Peregrine Pharmaceuticals; Roche; Sanofi
 
Gregory A. Masters
No Relationships to Disclose
 
Ronald J. Scheff
No Relationships to Disclose
 
Alexander Starodub
No Relationships to Disclose
 
Wells A. Messersmith
Consulting or Advisory Role - Immunomedics; OncoMed
Research Funding - GlaxoSmithKline; Immunomedics; Millennium; OncoMed; Pfizer; Roche/Genentech
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Immunomedics; Novartis
 
Allyson J. Ocean
No Relationships to Disclose
 
Leora Horn
Honoraria - Biodesix
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Merck; Puma Biotechnology; Xcovery
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst)
 
Jordan Berlin
Consulting or Advisory Role - Boston Biomedical; Celgene; EMD Serono; Genentech/Roche; Ipsen; Janssen Oncology; Lilly/ImClone; Novartis; Pharmacyclics; Symphony Evolution; Targovax; Threshold Pharmaceuticals; Vertex
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Abbvie; Boston Biomedical; Celgene; Genentech/Roche; Janssen Oncology
Other Relationship - Momenta Pharmaceuticals; Symphony Evolution
 
Pius P Maliakal
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Robert M. Sharkey
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Francois Wilhelm
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Onconova Therapeutics
 
David M. Goldenberg
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Patent protection for multiple antibody-based products and procedures
 
Michael J. Guarino
No Relationships to Disclose